Phase III, large-scale chemoprevention trials: Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer - The US national cancer institute experience

Hematology/Oncology Clinics of North America

Volumn 12, Issue 5, 1998, Pages 1019-1036

  Dunn, B K ^a   Kramer, B S ^a   Ford, L G ^a  

^a Early Detection COP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN; TUMOR MARKER;

BLOOD CLOTTING DISORDER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031717435     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70039-3     Document Type: Article

References (51)

1. V.J. Assikis V.C. Jordan Gynecologic effects of tamoxifen and the association with endometrial carcinoma Int J Gynecol Obstet 49 1995 241 257
2. R.R. Barakat The effect of tamoxifen on the endometrium Oncology 9 1995 129 139
3. W. Bodmer T. Bishop P. Karran Genetic steps in colorectal cancer Nat Genet 6 1994 217 219
4. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trial Lancet 2 1987 171 175
5. R.S. Bresalier N.W. Toribara Familial colon cancer G.L. Eastwood Premalignant Conditions of the Gastrointestinal Tract 1991 Elsevier New York 227 243
6. D.P. Byar The design of cancer prevention trials Recent Results Cancer Res 111 1988 34 48
7. W. Clark The role of tumor progression and the progression of cancer P. Greenwald B. Kramer D. Weed Cancer Prevention and Control 1995 Marcel Dekker New York 135 159
8. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1992 1 15
9. E.R. Fearon B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
10. B. Fisher Highlights of the NSABP Breast Cancer Prevention Trial Cancer Control 4 1997 78 86
11. B. Fisher J.P. Costantino C.K. Redmond Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
12. B. Fisher J. Dignam J. Bryant Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 88 1996 1529 1542
13. B. Fisher J. Costantino C. Redmond Randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor–positive tumors N Engl J Med 320 1989 479 484
14. T. Fornander B. Cedermark A. Mattsson Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers Lancet 1 1989 117 120
15. B.J. Furr V.C. Jordan The pharmacology and clinical uses of tamoxifen Pharmacol Ther 25 1984 127 205
16. M.H. Gail L.A. Brinton D.P. Byar Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1989 1879 1886
17. M.B. Gorin R. Day J.P. Costantino Long-term tamoxifen use and potential ocular toxicity Am J Ophthamol 125 1998 493 501
18. M.M. Gottardis V.C. Jordan Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea–induced rat mammary carcinoma model Cancer Res 47 1987 4020 4024
19. P. Greenwald J.W. Cullen The new emphasis in cancer control J Natl Cancer Inst 74 1985 543 551
20. D.F. Hayes R.C. Bast C.E. Desch Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers J Natl Cancer Inst 88 1996 1456 1466
21. A.L. Jones T.J. Powles Prevention of breast cancer Curr Opin Oncol 3 1991 1024 1028
22. G.J. Kelloff E.T. Hawk J.A. Crowell Strategies for identification and clinical evaluation of promising chemopreventive agents Oncology 10 1996 1471 1488
23. G.J. Kelloff C.W. Boone J.A. Crowell Risk biomarkers and current strategies for cancer chemoprevention J Cell Biochem 25S 1996 1 14
24. K.W. Kinzler B. Vogelstein Lessons from hereditary colorectal cancer Cell 87 1996 159 170
25. B.S. Kramer S. Srivastava Molecular biology in lung cancer prevention: From the bench to the bedside S. Srivastava S.M. Lippman W.K. Hong J.L. Mulshine Early Detection of Cancer: Molecular Markers 1994 Futura Armonk, NY 1 12
26. B.S. Kramer O.W. Brawley S. Nayfield NCI studies in primary prevention of breast and prostate cancer Cancer Research Therapy and Control 3 1993 203 211
27. S.H. Landis T. Murray S. Bolden P.A. Wingo Cancer statistics, 1998 CA Cancer J Clin 48 1998 6 29
28. S.M. Lippman W.K. Hong S.E. Benner The chemoprevention of cancer P. Greenwald B. Kramer D. Weed Cancer Prevention and Control 1995 Marcel Dekker New York 329 352
29. R.R. Love T.S. Surawicz E.C. Williams Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy Arch Intern Med 152 1992 317 320
30. W. Malone G.J. Kelloff H. Pierson P. Greenwald Chemoprevention of bladder cancer Cancer 60 Aug 1 suppl 1987 650 657
31. R.C. Moon V.E. Steele G.J. Kelloff Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: Toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone Anticancer Res 14 1994 889 894
32. S.G. Nayfield J.E. Karp L.G. Ford Potential role of tamoxifen in prevention of breast cancer J Natl Cancer Inst 83 1991 1450 1459
33. PDQ 1998 Prevention of cancer: Cancer prevention Bethesda, MD [database online http://cancernet.nci.nih.gov/pdq.htm ], National Cancer Institute
34. PDQ[database online: http://cancernet.nci.nih.gov/pdq.htm ], National Cancer Institute, Bethesda, MD, 1998: Prevention/early detection trials
35. F.P. Perera Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention J Natl Cancer Inst 88 1996 496 509
36. S.M. Powell N. Zilz Y. Beazer-Barclay APC mutations occur early during colorectal tumorigenesis Nature 359 1992 235 237
37. T. Powles R. Ecles S. Ashley Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial Lancet 352 1998 98 101
38. T.J. Powles A.L. Jones M.E.R. Ashley The Royal Marsden Hospital pilot tamoxifen chemoprevention trial Breast Cancer Res Treat 31 1994 73 82
39. R. Prentice Experimental methods in cancer prevention research P. Greenwald B. Kramer D. Weed Cancer Prevention and Control 1995 Marcel Dekker New York 213 224
40. K.I. Pritchard Is tamoxifen effective in prevention of breast cancer? Lancet 352 1998 80 81
41. J. Ragaz A. Coldman Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes J Clin Oncol 16 1998 2018 2024
42. L.E. Rutqvist B. Cedermark U. Glas The Stockholm trial on adjuvant tamoxifen in early breast cancer Breast Cancer Res Treat 10 1987 255 266
43. L.E. Rutqvist H. Johansson T. Signomklao Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies J Natl Cancer Inst 87 1995 645 651
44. A. Schatzkin L. Freedman M. Schiffman An epdemiologic perspective on biomarkers J Intern Med 233 1993 75 79
45. A. Schatzkin L.S. Freedman M.H. Schiffman S.M. Dawsey Validation of intermediate end points in cancer research J Natl Cancer Inst 82 1990 1746 1752
46. S. Srivastava B.S. Kramer Genetics of lung cancer: Implications for early detection and prevention H.H. Hansen Lung Cancer 1994 Kluwer Academic Publishers Norwell, MA 91 110
47. E. Szabo G.L. Shaw Intermediate markers and molecular genetics of lung carcinogenesis Cancer Control 4 1997 109 117
48. N.W. Toribara M.H. Sleisenger Screening for colorectal cancer N Engl J Med 332 1995 861 867
49. U. Veronesi P. Maisonneuve A. Costa on behalf of the Italian Tamoxifen Prevention Study Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hyperectimized women Lancet 352 1998 93 97
50. B. Vogelstein E.R. Fearon S.R. Hamilton Genetic alterations during colorectal tumor development N Engl J Med 319 1988 525 532
51. Wickerham DL, Costantino JP, Fisher B, et-al : The initial results from NSABP Protocol P-1: A clinical trial to determine the worth of tamoxifen for preventing breast cancer in women at increased risk. Presented at the 34th Annual Meeting, ASCO, 1998, Plenary Session